RDHL vs CMPX vs PRAX vs CRL vs AGEN

For growth investors, RedHill Biopharma Ltd.

(RDHL) is the stronger pick with 23. 2% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Compass Therapeutics, Inc. (CMPX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -14. 9%, compared to -100. 0% for RedHill Biopharma Ltd. (RDHL). Over 10 years, the gap is even starker: CRL returned +114. 0% versus RDHL's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Compass Therapeutics, Inc.

(CMPX) is the lower-risk stock at 1. 22β versus Agenus Inc. 's 2. 58β — meaning AGEN is approximately 112% more volatile than CMPX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), RedHill Biopharma Ltd.

(RDHL) is pulling ahead at 23. 2% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, AGEN leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Agenus Inc.

(AGEN) is the more profitable company, earning 0. 1% net margin versus -102. 8% for RedHill Biopharma Ltd. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRL leads at 12. 6% versus -181. 7% for RDHL. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Agenus Inc.

(AGEN) trades at 2. 9x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 13. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CMPX: 512. 0% to $11. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Compass Therapeutics, Inc.

(CMPX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 22)). Agenus Inc. (AGEN) carries a higher beta of 2. 58 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CMPX: -78. 5%, AGEN: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RDHL is a small-cap high-growth stock; CMPX is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.